Search PubMed⌕ Search

Biomedical subjects

M Lai

Publications and source records attributed to M Lai.

At least 145 records · Page 8Linked to original sources
PubMed1983

[Clinical effects of human lymphoblastoid interferon in patients with hematologic neoplasms].

Sixteen patients with hematologic neoplasms were treated with Human Lymphoblastoid Interferon (HL-BI) derived from Namalwa cell line. They were 6 multiple myeloma, 8 acute leukemia and 2 malignant lymphoma patients. All patients were previously treated with anticancer agents except one case with multiple myeloma. HLBI, 3.0 X 10(6) IU/day, was daily administered by intramuscular injection at least for 4 weeks. Three of 6 multiple myeloma responded to HLBI with a decrease of more than 25% in serum myeloma protein level. A case with pleural effusion due to massive infiltration of myeloma cells treated with intrathoratic administration of HLBI, in whom complete disappearance of pleural effusion was recognized. On the other hand, no patients with acute leukemia and malignant lymphoma responded except one case with acute lymphocytic leukemia, in which bone marrow lymphoblasts decreased transiently. Fever episodes, 13 of 16 cases, were more frequently seen but were manageable. Transient leukocytopenia and thrombocytopenia were also observed in 4 and 7 of 8 cases, respectively. No anaphylactoid reaction was seen. Thus, HLBI was expected useful in the clinical management of multiple myeloma.

Adult↗
PubMed1982

Treatment of relapsed acute myelocytic leukemia with a combination of aclarubicin and cytosine arabinoside.

Relapses in nine patients with acute myelocytic leukemia were treated with a combination of aclarubicin (ACR) and cytosine arabinoside (ara-C). ACR, 40 mg/m2/day, was administered daily by intravenous injection from day 1 to day 3 and ara-C, 60-80 mg/m2/day, divided into 2 doses, was given every 12 h by intravenous infusion from day 1 to day 7. Depending on the state of the bone marrow, ACR-ara-C regimen was modified in administration period and repeated after the resting periods of at least 7 days. Complete remission was obtained in 7 of 9 patients (77.8%). The time required for achieving the complete remission varied from 20 to 55 days with a median of 39 days. The duration of complete remission was from 8 to 52 weeks with a median of 22 weeks. Side effects on digestive system such as nausea, vomiting and anorexia, were seen in all patients, although they were managed by symptomatic treatment. The results indicate the effectiveness of this ACR-ara-C regimen in the clinical management of acute nonlymphocytic leukemia.

Aclarubicin↗
PubMed1982

[Clinical management of acute lymphocytic leukemia in adults. 1. Treatment of acute lymphocytic leukemia with VP (vincristine, prednisolone)--DVMP (daunorubicin, vincristine 6-mercaptopurine, prednisolone) regimen].

Eighteen patients with acute lymphocytic leukemia (ALL) were treated with VP (vincristine, prednisolone) followed by DVMP (daunorubicin + vincristine + 6-mercaptopurine + prednisolone) regimen (VP-DVMP regimen). Patients were all previously untreated. Complete remission (CR) was obtained in 11 of 18 patients (61.1%,) by VP alone and 4 patients, by VP-DVMP. The time required for CR varied from 14 to 60 days with a median of 28 days. The duration of CR and survivals in responders were from 1.2 to 42.3 + months with a median of 24.0 months. The hematological toxicities in VP-DVMP regimen were lower than those in NVP (neocarzinostatin + vincristine + prednisolone) and NVMP (neocarzinostatin + vincristine + 6-mercaptopurine + prednisolone) regimens.

Adolescent↗
PubMed1982

[Comparative evaluation of a combination of daunorubicin and cytosine arabinoside and that of aclarubicin and cytosine arabinoside in remission induction in acute non-lymphocytic leukemia].

A comparative trial of a combination of daunorubicin and cytosine arabinoside (Regimen A) and a combination of aclarubicin and cytosine arabinoside (Regimen B) was performed. Sixteen patients with acute non-lymphocytic leukemia, previously untreated, were entered into this study. Five of 8 patients (62.5%) obtained a complete remission (CR) in Regimen A and B, respectively. The days required for achieving a CR varied from 37 to 46 days in Regimen A and from 22 to 56 days in Regimen B. The total doses of daunorubicin and cytosine arabinoside were from 100 to 240 mg and from 640 to 1,120 mg in Regimen A, respectively. Those of aclarubicin were from 180 to 300 mg and from 660 to 1,000 mg in cytosine arabinoside in Regimen B. In a comparative study on hematological changes, toxic effects on peripheral white blood cell, platelet and nucleated cell counts in bone marrow tended to appear later in Regimen B compared to those in Regimen A. Side effects on digestive system such as nausea and vomiting and vascular pain were more frequently recognized in patients treated with Regimen B, although they were managed by symptomatic treatment. The results indicated the usefullness of aclarubicin in combination chemotherapy for the treatment of acute non-lymphocytic leukemia.

Aclarubicin↗
PubMed1981

Chromosome 14q+ in adult T-cell leukemia.

Cytogenetic studies were performed on leukemic cells from two patients with adult T-cell leukemia. A 14q+ marker chromosome was found in the peripheral blood leukocytes from patient No. 1 and in a leukemic T-cell line (MT-1) derived from the peripheral blood of patient No. 2. The 14q+ resulted from a t(12;14) in patient No. 1 and from a t(Y;14) in patient No. 2 with a break point at 14q32 in each case. In addition, the leukemic cells from patient No. 1 showed a t(1;7) and a 9q-, while the MT-1 line had numerous structural abnormalities. Thus, it is clear that a 14q+ translocation is not restricted to B-cell neoplasms but occurs in T-cell neoplasms as well.

Adult↗
PubMed1980

Effect of chlorpromazine on cell proliferation in the developing rat brain. A combined biochemical and morphological study.

Chlorpromazine, a widely used drug in current clinical practice, produced a severe reduction of the rate of [3H]thymidine incorporation into brain DNA of 11-day-old rats. The depression of in vivo synthesis rate was detectable by 6 h after chlorpromazine administration (50 mg/kg, s.c.) and the rate was less than 40% and 60% of controls during period 14-30 h in forebrain and 6-30 h in cerebellum respectively. The depression was dose-dependent and half maximal effect was produced with about 10 mg/kg chlorpromazine. The drug caused some retardation in the rate of conversion of [3H]thymidine to [3H]thymine nucleotides in the brain, but the severe depression in DNA labelling was also evident after correcting the values on the basis of [3H]thymine nucleotides concentration. Mitotic activity was significantly reduced in the cerebellar external granular layer. Increased numbers of cell degenerations, shown by Feulgen cytophotometry to be postmitotic, were seen in both layers 12 and 32 h after chlorpromazine. Analysis of cell cycle parameters showed no significant changes. However, the labelling index in subependymal cells was reduced, indicating an increase in turnover time of about 40%. The results are consistent with an action of chlorpromazine on cell proliferation, either by direct effects on the generation and survival of cells, or via its major pharmacological actions on neurotransmitter balance. These effects are potentially of functional and clinical significance.

Age Factors↗
PubMed1980

Effects of undernutrition on gliogenesis and glial maturation in rat corpus callosum.

Rats were undernourished by halving the mother's food intake from the sixth day of pregnancy onwards and through lactation. At weaning, the young rats were restricted to half the normal weight of food. A combination of light and electron microscopic techniques was used to study the effects of this regime on gliogenesis and glial maturation in the corpus callosum of animals aged between 15 and 48 days. A disturbance of neuroglial proliferation was suggested by the finding of an increased proportion of astroglia relative to oligodendroglia in the 15-day-old undernourished rats, indicating a delay in the acquisition of cells produced relatively late in development. Impaired differentiation of oligodendroglia was suggested by the finding in treated animals of increased light oligodendrocytes at 15 days and a deficit of dark oligodendrocytes at 48 days, relative to controls. The previously observed retardation in myelin acquisition seems thus to be related to a delay in the differentiation of oligodendroglia, although it seems likely that the proliferation of these cells is also disturbed in undernutrition.

Animals↗
PubMed1980

Effects of undernutrition on myelination in rat corpus callosum.

Rats were undernourished by halving the mother's food intake from the sixth day of pregnancy onwards and through lactation. Subsequently, the young animals were maintained up to 48 days on half the normal diet. The effects of this regime of treatment on myelination in the corpus callosum were investigated by light and electron microscopy. In comparison with controls, the percentage of axons myelinated at 15, 21, and 48 days was reduced in undernourished rats. The number of lamellae constituting the myelin sheath was also reduced at 15 and 21 days, but at 48 days no difference was seen between control and treated rats, suggesting that a catch-up in myelination had occurred. A linear relationship between myelin sheath thickness and axonal diameter was observed in both groups of animals. However, a long-term effect on axonal growth was suggested by findings in the 48-day undernourished animals; in comparison with controls, axonal diameter was reduced, relative to myelin sheath thickness.

Animals↗
PubMed1980

A case of hand mirror cell variant of acute lymphoblastic leukemia.

A 30 year old female patient diagnosed as acute lymphoblastic leukemia (ALL) with hand mirror like configuration of lymphoblastic-lymphocytic cells is reported. Although the leukemia was resistant to conventional chemotherapeutic regimens, the patient always looked well and survived for more than 20 months. Surface marker analysis showed that the cell was non-T, non-B, and not reactive to antiserum against common ALL antigen. A cytogenetic study of all the analyzable metaphases of the direct bone marrow preparation had a normal female karyotype. The clinical and hematological course is described. The immunological significance and the influence of hand mirror cell on chemosensitivity and prognosis are discussed.

Adult↗
PubMed1980

Treatment of refractory acute leukemia with aclacinomycin-A.

Twelve patients with refractory acute leukemia (7 patients with acute myelocytic leukemia and 5 patients with acute lymphocytic leukemia) were treated with a new anthracycline antibiotic, aclacinomycin-A (ACM). ACM was administrated by intravenous drip infusion at a dose of 20 mg/day for 7 or 14 days and this was repeated after at least 7 days. Four of 12 patients (33.3%) achieved a complete remission; 3 of 7 acute myelocytic leukemia (42.8%) and 1 of 5 acute lymphocytic leukemia (20.0%). The days required for achieving the complete remission ranged from 23 to 78 days (median: 61) and the total doses of ACM used from 180 to 500 mg (median: 310), and the durations of complete remission from 11 to 28+ weeks (median: 21+). The untoward effects on digestive organs, such as nausea, vomiting and anorexia, and hematological toxicities were frequently seen; however, they were controlled by supportive treatment. Alopecia was not observed. Arrythmia was recognized in one patient at the initiation of ACM infusion with complete remission without withdrawal of ACM. These results suggest that ACM is a potentially effective anthracycline antibiotic in the clinical management of acute leukemia.

Aclarubicin↗
PubMed1979

Effects of thyroxine on postnatal cell acquisition in the rat brain.

The effects of treatment with L-thyroxine (3 micrograms by subcutaneous injection daily from birth) on cell acquisition in the rat brain were studied during the first 3 postnatal weeks. In the forebrain, thyroxine has no effect on cell proliferation in the first 6 days, but it causes decreased cell acquisition from 12 to 21 days so that cell number becomes significantly reduced. Estimates of cell proliferation kinetics and of cell death in the lateral ventricular subependymal layer show no apparent abnormality. In the cerebellum, treatment from birth leads to increased cell proliferation during the first week: in comparison with controls, the rate of [3H]thymidine incorporation into DNA, thymidine kinase activity, and the number of cells both in the major germinal site (external granular layer: EGL) and in the whole cerebellum are elevated. This initial effect of thyroxine appears by day 3 and is short-lived, being no longer evident after day 6. The build-up of cell numbers in the EGL at day 6 seems to be related to a preceding, transient retardation of cell migration from this layer rather than to an acceleration of cell replication, since cell cycle parameters are normal. From day 12 the rate of [3H]thymidine incorporation into DNA is severely reduced in treated rats. Advancement of cellular differentiation rather than increased cell death in the EGL appears to be involved in this phenomenon.

Aging↗
PubMed1979

Heteroduplex analysis of the sequence relationships between the genomes of Kirsten and Harvey sarcoma viruses, their respective parental murine leukemia viruses, and the rat endogenous 30S RNA.

The sequence relations between Kirsten murine sarcoma virus (Ki-SV), Harvey murine sarcoma virus (Ha-SV), and a rat endogenous 30S RNA were studied by electron microscope heteroduplex analysis. The sequence relationships between the sarcoma viruses and their respective parental murine leukemia viruses (Kirsten and Moloney murine leukemia viruses), as well as between the two murine leukemia viruses, were also studied. The only observed nonhomology feature of the Kirsten murine leukemia virus/Moloney murine leukemia virus heteroduplexes was a substitution loop with two arms of equal length extending from 1.80 +/- 0.18 kilobases (kb) to 2.65 +/- 0.27 kb from the 3' end of the RNA. It is believed that this feature lies in the env gene region of the viral genomes. The Ha-SV and Moloney murine leukemia virus genomes (respective lengths, 6.0 and 9.0 kb) were homologous in a 1.0 +/- 0.05-kb region at the 3' end and possibly over a 200-nucleotide region at the 5' ends; otherwise, they were nonhomologous. Ha-SV and Ki-SV (length, 7.5 kb) were homologous in the first 4.36 +/- 0.37-kb region from the 3' end and in a 0.70 +/- 0.15-kb region at the 5' end. In between, there was a nonhomology region, possibly containing a short (0.23-kb) region of partial or total homology. The heteroduplex analysis between rat endogenous 30S RNA and Ki-SV shows that there are mixed regions of sequence homology and nonhomology at both the 5' and 3' ends. However, there is a large (4-kb) region of homology between Ki-SV and the rat 30S RNA in the center of the genomes, with only a small nonhomology hairpin feature. These studies help to define the regions of homology between the Ha-SV and Ki-SV genomes with each other and with the rat endogenous 30S RNA. These regions may be related to the sarcoma genicity of the viruses. In particular, the 0.7-kb region of homology of Ha-SV with Ki-SV at the 5' ends may be related to the formation of a 21,000-dalton phosphoprotein in cells transformed by either virus.

Animals↗
PubMed1977

Aqueous humor ascorbate concentration and open-angle glaucoma.

The mean value for aqueous concentration in 35 patients with open-angle glaucoma was 22.4 +/- 12.9 mg/100 ml. The mean value for aqueous ascorbate in four patients with uncomplicated senile cataract was 11.55 +/- 3.01 mg/100 ml. The results indicate that the majority of open-angle glaucomatous eyes do not involve a deficiency of ascorbate, and suggest that ascorbate has no therapeutic value in the management of primary open-angle glaucoma. The magnitude of aqueous ascorbate variation among glaucoma eyes is probably related to the factors that influence the patency of trabecular meshwork, not the metabolic activity of the ciliary processes.

Animals↗